Saturday 17 October 2026
Export TSHA’s income statement to Excel — free account
Taysha Gene Therapies, Inc.
TSHA Healthcare Biotechnology
Taysha Gene Therapies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.8 million, up 17.3% from fiscal 2024. In the quarter to June 2026, revenue grew 206.8%, EPS fell 44.4%, free cash flow fell 100.3% and total debt rose 20.0%, each against the same quarter a year earlier.
3.62
0.11
−2.95%
Follow TSHA
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | 4 | 4 |
P/E ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | 0.00 | 12.85 | 51.93 | 149.08 |
Altman Z-Score |
— | — | — | — | (7.88) | (3.41) | (3.30) | 8.05 |
P/FCF ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | (17.25) | (7.40) | (10.49) | (0.53) |
P/Operating CF |
— | — | — | — | 6.57 | (12.32) | (23.64) | (65.80) |
P/B ratio |
— | — | — | — | 101.89 | 2.65 | 6.05 | 7.12 |
Price to Tangible BV |
— | — | — | — | 101.89 | 2.65 | 6.05 | 7.12 |
EV/Sales |
— | — | — | — | 0.00 | 6.13 | 40.46 | 126.18 |
EV/EBITDA |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | (0.53) | (1.30) | (4.15) | (15.99) |
EV/FCF |
— | — | — | — | (0.41) | (1.16) | (3.92) | (15.14) |
Quick Ratio |
— | 0.00 | 35.24 | 2.88 | 1.40 | 3.93 | 5.32 | 12.06 |
Current Ratio |
— | 0.10 | 36.17 | 3.08 | 1.54 | 4.08 | 5.42 | 12.23 |
Net Debt/EBITDA |
— | 0.00 | 5.84 | 0.65 | 0.31 | 1.46 | 1.06 | 2.47 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 17.38% | 30.07% | 23.45% | 27.40% | 14.59% |
Debt/Equity |
— | 0.00 | 0.00 | 0.39 | 40.01 | 0.54 | 0.61 | 0.20 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.01 | 0.10 | 0.05 | 0.04 |
Operating CF/Net income |
— | 0.00 | 0.51 | 0.67 | 0.53 | 0.65 | 0.91 | 0.85 |
Capex/Depreciation |
— | 0.00 | (1,009.11) | (43.81) | (21.22) | (5.37) | (0.30) | (0.64) |
Interest Coverage |
— | — | (1,535.79) | (121.34) | (42.77) | (14.49) | (896.66) | (1,753.94) |
| — | (0.89%) | (47.79%) | (100.68%) | (344.67%) | (294.04%) | (121.94%) | (68.45%) | |
| — | (14,866.67%) | (46.36%) | (73.82%) | (97.59%) | (74.62%) | (53.62%) | (43.28%) | |
ROIC |
— | 0.00% | (54,849.49%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | 825.93% | (23.91%) | (110.13%) | (341.66%) | (90.02%) | (72.37%) | (35.76%) |
Average Days of Receivables |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 3,643.84% | 367.47% | 792.04% | 884.10% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 1,493.21% | 194.47% | 347.45% | 346.55% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 721.14% | 51.16% | 157.24% | 136.07% |
Graham Net Nets |
— | — | — | — | (0.30) | 0.26 | 0.12 | 0.13 |
Graham Number |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | (171.82%) | (39.18%) | (20.81%) | (6.18%) |
Free Cash Flow Yield |
— | — | — | — | (117.13%) | (40.99%) | (19.90%) | (5.59%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.06 | 0.13 | 0.03 | 0.03 |
Operating CF per Share |
— | 0.00 | (1.74) | (3.11) | (2.01) | (0.63) | (0.32) | (0.29) |
Capex per Share |
— | 0.00 | (0.51) | (0.57) | (0.57) | (0.06) | 0.00 | 0.00 |
Free Cash Flow per Share |
— | 0.00 | (2.25) | (3.68) | (2.58) | (0.69) | (0.33) | (0.29) |
Cash per Share |
— | 0.00 | 14.22 | 3.96 | 2.00 | 1.24 | 0.56 | 1.00 |
Shareholders Equity per Share |
— | 0.00 | 14.23 | 2.53 | 0.02 | 0.65 | 0.29 | 0.77 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.00 | 14.23 | 2.53 | 0.02 | 0.65 | 0.29 | 0.77 |
Free Cash Flow |
— | 0.00 | (39.81) | (138.60) | (113.26) | (80.39) | (81.60) | (93.83) |
Working Capital |
— | (0.13) | 250.75 | 107.86 | 33.63 | 113.11 | 115.90 | 298.10 |
Capital Expenditures |
— | 0.00 | (9.08) | (21.55) | (24.87) | (7.37) | (0.37) | (0.74) |
Net Current Asset Value |
— | (0.13) | 250.30 | 41.03 | (28.91) | 52.07 | 53.29 | 228.27 |
EV/EBIT |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 9.94 | 0.48 | 0.04 | 0.08 |
Price to Operating Income |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.00 | 0.03 | 0.01 | 0.08 | 0.13 | 0.17 | 0.17 |
Cash ROIC |
— | 0.00% | (7.92%) | (49.20%) | (89.32%) | (30.94%) | (32.01%) | (15.20%) |
Accounts Receivable Turnover |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Payables |
— | — | — | 11.88 | 16.35 | 8.66 | 4.98 | 4.93 |
Average Assets |
— | 0.01 | 129.45 | 236.42 | 170.12 | 149.50 | 166.55 | 251.84 |
Average Common Equity |
— | 125.58 | 125.58 | 173.34 | 48.17 | 37.94 | 73.23 | 159.23 |
Columns are period end dates